과제정보
연구 과제 주관 기관 : Pasteur Institute of Iran
참고문헌
- Aman W, Mousa S, Shiha G, et al (2012). Current status and future directions in the management of chronic hepatitis C. Virol J, 2, 9-57.
- Andrea S, Antonia D, Clementi M (2012). New therapeutic options for HCV infection in the monoclonal antibody era. New Microbiologica, 35, 387-97.
- Chia-Yen Dai, Wan-Long Chuang, Wen-Yu Chang, et al (2006). Tumor necrosis factor-a promoter polymorphism at position _308 predicts response to combination therapy in hepatitis c virus infection. J Infectious Diseases, 193, 98-101. https://doi.org/10.1086/498244
- Chloe L (2008). Host genetic factors and antiviral immune responses to HCV. Clin Liver Dis, 12, 713-26. https://doi.org/10.1016/j.cld.2008.03.002
- Gane EJ, Stedman CA, Hyland RH, et al (2013). Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med, 368, 34-44. https://doi.org/10.1056/NEJMoa1208953
- Gaurav Dogra, Anita Chakravarti, Premashish Kar, et al (2011). Polymorphism of tumor necrosisfactor-a and interleukin-10 gene promoter region in chronic hepatitis C virus patients and their effect on pegylated interferon-a therapy response. Human Immunol, 72, 935-9. https://doi.org/10.1016/j.humimm.2011.06.008
-
Guo X, Zhao Z, Xie J, et al (2012). Prediction of response to pegylated-interferon-
${\alpha}$ and ribavirin therapy in Chinese patients infected with different Hepatitis C virus genotype. Virol J, 9, 123. https://doi.org/10.1186/1743-422X-9-123 - Heba F. Pasha, Mohamed I. Radwan, Hoda A, et al (2013). Cytokines genes polymorphisms in chronic hepatitis C: Impact on susceptibility to infection and response to therapy. Cytokine, 61, 478-84. https://doi.org/10.1016/j.cyto.2012.11.003
- Henderson DK (2003). Managing occupational risksfor hepatitis c transmission in the health care setting. Clin Microbiol Rev, 16, 546-68. https://doi.org/10.1128/CMR.16.3.546-568.2003
- Hoofnagle JH (2002). Course and outcome of hepatitis C. Hepatol, 36, 21-9. https://doi.org/10.1002/hep.1840360704
- Kau A, Vermehren J, Sarrazin C (2008). Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol, 49, 634-51. https://doi.org/10.1016/j.jhep.2008.07.013
- Khodabandehloo M, Daem Roshani (2014). Prevalence of hepatitis c virus genotypes in iranian patients: a systematic review and meta-analysis. Hepat Mon, 14, 22915.
- Klevens RM, Hu DJ, Jiles R, et al (2012). Evolving epidemiology of hepatitis c virus in the united states. Clin Infect Dis, 55, 3-9. https://doi.org/10.1093/cid/cis393
- Manns MP, McHutchison JG, Gordon SC, et al (2001). Peginterferon alfa-2b plus ribavirin compared withinterferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C. Lancet, 358, 958-65. https://doi.org/10.1016/S0140-6736(01)06102-5
- Mirjam B, Joachim A, Isabel A (2013). Host-targeting agents for prevention and treatment of chronic Hepatitis C " Perspectives and challenges, J Hepatol, 58, 375-84. https://doi.org/10.1016/j.jhep.2012.09.022
- Mohamed I. Radwan a, Heba F. Pasha b, Rasha H. Mohamed c, et al (2012). Influence of transforming growth factor-b1 and tumor necrosis factor-a genes polymorphisms on the development of cirrhosis and hepatocellular carcinoma in chronic hepatitis C patients. Cytokine, 60, 271-6. https://doi.org/10.1016/j.cyto.2012.05.010
- Mohd Hanafiah K, Groeger J, Flaxman AD, et al (2013). Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatol, 57, 1333-42. https://doi.org/10.1002/hep.26141
- Ray Kim W (2010). Global epidemiology and burden of hepatitis C. Microbes Infect, 4, 1219-25.1.
- Roba M. Talaat , Ahmed A. Esmail , Reda Elwakil , et al (2011). Tumor necrosis factora, -308 g/a polymorphism 1and risk of hepatocellularcarcinoma in hepatit c virus infect pateints department of tropical medicine. Chinese J Cancer, 31, 29-35.
- Sy T, Jamal MM (2006). Epidemiology of Hepatitis C Virus (HCV) Infection. Int J Med, 3, 41-6.
- Thio CL (2008). Host genetic factors and antiviralimmune responses to HCV. Clin Liver Dis, 12, 713-26. https://doi.org/10.1016/j.cld.2008.03.002
- Zeisel MB, Lupberger J, Fofana I, et al (2013). TF.Host-targeting agents for prevention and treatment of chronic hepatitis C "Perspectives and challenges. J Hepatol, 58, 375-84. https://doi.org/10.1016/j.jhep.2012.09.022